VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
About the study
The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Key Inclusion Criteria:
- Males and females, 40 to 75 years of age (inclusive)
- Diagnosis of PD, consistent with United Kingdom Brain Bank Criteria
- Motor responsiveness to dopaminergic therapy, demonstrated by improvement in MDS-UPDRS III score
- Disease duration from diagnosis of ≥4 years
- An average of ≥3 hours of OFF time (ie, periods of insufficient control of motor PD symptoms) per day over 3 consecutive days as confirmed by the PD Diary
- A stable, optimal regimen of Parkinson's medications including levodopa for at least weeks prior to screening evaluation. Participants must have a minimum duration of levodopa treatment of ≥1 year
- In the judgment of the Investigator, stable Parkinson's features and symptoms for at least 4 weeks prior to screening evaluation
- Agrees to defer any elective neurological surgery, including deep brain stimulation or ablation procedure for PD, levodopa or apomorphine infusion, or the addition of new dopaminergic formulations until after the study is completed, if medically appropriate
- Ability to travel to study visits
EXCLUSION CRITERIA
Key Exclusion Criteria:
- Atypical or secondary parkinsonism, including but not limited to symptoms believed to be due to trauma, brain tumor, infection, cerebrovascular disease, other neurological disease, or to drugs, chemicals, or toxins, as determined by the Investigator
- MoCA score <26
- New or unstable psychiatric conditions (psychosis, depression) within 1 year of screening
- Brain imaging abnormalities in the striatum or other regions that would substantially increase risk of surgery
- Contraindication to MRI and/or gadolinium-based contrast agents
- Prior brain surgery, infusion therapies or planned treatments that could complicate the study procedure or negatively impact study evaluations as determined from participant interview, screening MRI, or medical records
- History of malignancy other than treated carcinoma in situ within 3 years of screening evaluation
- Prior gene transfer, current treatment with any investigational agent (drug or device) within 2 months of screening evaluation, or participation or plans to participate in another research study
- Severe, biphasic and/or uncontrolled dyskinesia
- Disabling or uncontrolled impulse control disorders
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Parkinson's Disease
Age (in years)
40 - 75
Phase
Phase 2
Participants needed
85
Est. Completion Date
Dec 31, 2023
Treatment type
Interventional
Sponsor
Neurocrine Biosciences
ClinicalTrials.gov identifier
NCT03562494
Study number
PD-1105
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?